The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Introducing a Phase Ib/II trial to evaluate tasquinimod for the treatment of myelofibrosis
Peter te Boekhorst, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, introduces a Phase Ib/II trial (NCT06327100) that will evaluate the safety and efficacy of tasquinimod in patients with myelofibrosis (MF) who are refractory or intolerant to JAK2 inhibitors. The study’s primary endpoint will be a reduction in spleen volume measured by magnetic resonance imaging (MRI) after 24 weeks. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
